Mao Cecilia

Director · Officer · CBOE, EFX

As of 2026-09-16, Mao Cecilia has 10 Form 4 transactions on record across 2 companies — 5 in the trailing 12 months.

Everything this person has disclosed to the SEC on Form 4 — across every company they file for — reconstructed from the public record. A filing history, not a tip sheet.

Reconstructed holdings

Direct: $2.8MIndirect: $0$2.8Mas of 2026-09-16
  • Direct $2.8M
  • Indirect $0
EFXdirect13,318 sh$2.2M
CBOEdirect2,441 sh$660K

Reconstructed from this person's own Form 4 filings — the total each filing reported owning afterward, priced at the close on the as-of date shown. A filed position can lag the real one.

Direct and indirect holdings (e.g. through a trust or fund) are tagged separately, as filed.

Trades by company

EFX · 8 trades
2026-02-25: Award / grant, 2,695 sh ($0)2026-02-18: Purchase, 2,400 sh ($465K)2026-02-10: Withheld for tax, 918 sh ($186K)2026-02-10: Award / grant, 1,374 sh ($0)2025-02-11: Withheld for tax, 346 sh ($88K)2025-02-11: Award / grant, 594 sh ($0)2025-02-10: Award / grant, 791 sh ($0)2025-02-10: Award / grant, 2,541 sh ($0)
CBOE · 2 trades
2026-05-14: Award / grant, 530 sh ($0)2025-05-06: Award / grant, 729 sh ($0)

Filing ledger

DateCompanyActionShares @ priceValueOwnership ΔOwned afterFiling
2026-02-18EFXPurchase2,400 @ $193.72$465K+29.2% of holding10,623Form 4
9 award / exercise / gift records — not counted as purchases
DateCompanyActionSharesOwned afterFiling
2026-05-14CBOEAward / grant5302,441Form 4
2026-02-25EFXAward / grant2,69513,318Form 4
2026-02-10EFXWithheld for tax9188,223Form 4
2026-02-10EFXAward / grant1,3749,141Form 4
2025-05-06CBOEAward / grant7291,911Form 4
2025-02-11EFXWithheld for tax3467,749Form 4
2025-02-11EFXAward / grant5948,095Form 4
2025-02-10EFXAward / grant7917,501Form 4
2025-02-10EFXAward / grant2,5412,541Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.